» Articles » PMID: 25805586

The Genetic Landscape of Diffuse Large B-cell Lymphoma

Overview
Journal Semin Hematol
Specialty Hematology
Date 2015 Mar 26
PMID 25805586
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in the western world, is an aggressive disease that remains incurable in approximately 30% of patients. Over the past decade, the rapid expansion of sequencing technologies allowing the genome-wide assessment of genomic and transcriptional changes has revolutionized our understanding of the genetic basis of DLBCL by providing a comprehensive and unbiased view of the genes/pathways that are disrupted by genetic alterations in this disease, and may contribute to tumor initiation and expansion. These studies uncovered the existence of several previously unappreciated alterations in key cellular pathways that may also influence treatment outcome. Indeed, a number of newly identified genetic lesions are currently being explored as markers for improved diagnosis and risk stratification, or are entering clinical trials as promising therapeutic targets. This review focuses on recent advances in the genomic characterization of DLBCL and discusses how information gained from these efforts has provided new insights into its biology, uncovering potential targets of prognostic and therapeutic relevance.

Citing Articles

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Masnikosa R, Cvetkovic Z, Piric D Int J Mol Sci. 2024; 25(21).

PMID: 39518937 PMC: 11545713. DOI: 10.3390/ijms252111384.


Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome.

Negara I, Tomuleasa C, Buruiana S, Efremov D Cancers (Basel). 2024; 16(12).

PMID: 38927876 PMC: 11201917. DOI: 10.3390/cancers16122170.


Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.

Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y Neurooncol Adv. 2024; 6(1):vdae037.

PMID: 38690230 PMC: 11059299. DOI: 10.1093/noajnl/vdae037.


New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?.

Abrisqueta P J Clin Med. 2024; 13(7).

PMID: 38610693 PMC: 11012802. DOI: 10.3390/jcm13071929.


Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma.

Cerchietti L Blood. 2024; 143(12):1101-1111.

PMID: 38211334 PMC: 10972714. DOI: 10.1182/blood.2023021002.


References
1.
Khodabakhshi A, Morin R, Fejes A, Mungall A, Mungall K, Bolger-Munro M . Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012; 3(11):1308-19. PMC: 3717795. DOI: 10.18632/oncotarget.653. View

2.
Green M, Gentles A, Nair R, Irish J, Kihira S, Liu C . Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013; 121(9):1604-11. PMC: 3587323. DOI: 10.1182/blood-2012-09-457283. View

3.
Trinh D, Scott D, Morin R, Mendez-Lago M, An J, Jones S . Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013; 121(18):3666-74. PMC: 3643765. DOI: 10.1182/blood-2013-01-479865. View

4.
Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

5.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View